EMC
53
-3
XRX
34
-3
RRC
60
-3
PM
58
2
NOC
40
-10
WHR
70
4
HCP
70
-4
TXN
49
-6
DE
36
-2
T
48
3
LB
63
-4
KEY
46
-2
CSX
68
3
PDCO
30
-6
LEN
52
2
XOM
51
3
NOV
58
-2
EMR
77
-2
FTI
78
-3
CF
53
2
EMC
53
-3
XRX
34
-3
RRC
60
-3
PM
58
2
NOC
40
-10
WHR
70
4
HCP
70
-4
TXN
49
-6
DE
36
-2
T
48
3
LB
63
-4
KEY
46
-2
CSX
68
3
PDCO
30
-6
LEN
52
2
XOM
51
3
NOV
58
-2
EMR
77
-2
FTI
78
-3
CF
53
2
Financhill
Back

Akebia Therapeutics Quote, Financials, Valuation and Earnings

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.
Buy
63

AKBA
Akebia Therapeutics

Last Price:
1.87
Seasonality Move:
44.29%

7 Day Trial

ALL ACCESS PASS

$ 7

"This Changes Everything" - Trump Hands Millions Massive IRS Gift

Learn More Here

Akebia Therapeutics Price Quote

$1.87
-0.05 (-2.6%)
(Updated: November 14, 2024 at 5:30 PM ET)

Akebia Therapeutics Key Stats

Buy
63
Akebia Therapeutics (AKBA) is a Buy
Day range:
$1.89 - $1.98
52-week range:
$0.80 - $2.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.18
P/B ratio:
0%
Volume:
2.1M
Avg. volume:
2.1M
1-year change:
107.95%
Market cap:
$403.8M
Revenue:
$194.6M
EPS:
$-0.21

How Much Does Akebia Therapeutics Make?

Is Akebia Therapeutics Growing As A Company?

  • What Is Akebia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.23%
  • What Is Akebia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Akebia Therapeutics Stock Price Performance

What Is Akebia Therapeutics 52-Week High & Low?

Akebia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akebia Therapeutics?

Is Akebia Therapeutics Cash Flow Positive?

  • What Is AKBA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$39M
  • What Is Akebia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $24.9M
  • What Is Akebia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$29K

Akebia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    AKBA return on invested capital is -671.06%
  • What Is Akebia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -17.19%
  • What Is AKBA Return On Equity?
    ROE is a measure of profitability and is 0%

Akebia Therapeutics Earnings Date & Stock Price

Akebia Therapeutics Competitors

  • Who Are Akebia Therapeutics's Competitors?
    Below is a list of companies who compete with Akebia Therapeutics or are related in some way:
    • Bioventus Inc (BVS)
    • Corcept Therapeutics Inc (CORT)
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Akebia Therapeutics Dividend Yield

Akebia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -100%
Revenue: -22.58% -15.9%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.50
Upside from Last Price: 186.46%

Major Shareholders

  • How many AKBA shares are owned by institutional investors?
    92.6M AKBA shares are owned by institutional investors
  • How many AKBA shares are owned by insiders?
    7.9M AKBA shares are owned by insiders